Search

everythinglearnresearchcommunity

for

Search:↓

New hair loss treatments like stem cells, hair cloning, and gt20029 are unlikely to be available in the next 5-10 years, with some trials possibly starting by 2026. Current treatments like Minoxidil and Finasteride have been used for decades, and new developments depend on funding and successful trials.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.

Osteopontin, a protein involved in hair growth on moles, may help with hair loss. However, it is also linked to Alzheimer's, cancer, and bone development, so caution is advised.

You cannot donate blood if you are taking finasteride or dutasteride due to potential risks to pregnant women. Finasteride has a shorter wait time to donate blood compared to dutasteride, and both oral and topical forms can disqualify you from donating.

The conversation is about acquiring GT20029 for hair loss treatment. The user is looking for information on how to obtain it.

Hair loss discussion mentions Verterporfin for scar-free healing and hair follicle regeneration. Human study expected within 2 years.

The conversation discusses hair loss treatments, including Minoxidil, finasteride, and RU58841. It highlights an interview with Stemson Therapeutics CEO Geoff Hamilton about advancements in hair cloning technology.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

A 17-year-old experiencing hair loss due to hard water was advised by a dermatologist to use a treatment containing Minoxidil and vitamins. A respondent confirmed the treatment's safety but warned that discontinuing Minoxidil could worsen hair loss.

A 17-year-old is using topical minoxidil for hair loss and is considering other treatments like ketoconazole shampoo and saw palmetto while waiting to start finasteride at 19. Suggestions include using oral minoxidil, topical antiandrogens like RU58841, and CB-03-01, with a focus on minimizing systemic DHT impact.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

A 24-year-old started using finasteride for hair loss after hesitating due to potential side effects, and is considering a hair transplant. Other users shared their experiences with finasteride, minoxidil, and rosemary oil, discussing effectiveness and side effects.

RU58841 helped clear forehead acne. The user mixes it with 5% minoxidil and considers making a cream for acne treatment.

The conversation is about skepticism towards a hair growth oil promoted by a social media influencer, with users suggesting it is ineffective without proven treatments like Minoxidil, finasteride, or hair transplants. The product contains various oils and extracts, but users doubt its effectiveness.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

The conversation discusses new hair loss treatments like stem cell therapy, exosome treatments, and DHI, with mentions of GT20029, Amp303, and Plated PRP Serum as promising options. It also notes the use of dutasteride, topical finasteride, and minoxidil, but the focus is on non-hormonal innovations.

Finasteride may affect liver function and cortisol levels, potentially linking it to non-alcoholic fatty liver disease (NAFLD). More research is needed to understand this connection fully.

The conversation discusses potential new treatments for androgenetic alopecia (AGA), including verteporfin, pyrilutamide, and hair cloning. There is optimism about scientific advancements providing alternatives to minoxidil and finasteride.

The conversation is about updates on Scube3 related to hair loss. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

The conversation discusses Shiseido's RepliCel Hair-01 technology for hair regeneration, which aims to stop hair loss with minimal regrowth. Treatments mentioned include Minoxidil, finasteride, and RU58841.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

A 17-year-old is concerned that taking finasteride might affect facial bone growth and is considering switching to topical finasteride due to its reduced systemic effects. They are also using oral minoxidil and exploring other hair loss treatments like microneedling and ketoconazole shampoo.

Finasteride can increase body and facial hair growth due to increased testosterone, despite its intended use to reduce hair loss on the scalp. Some users consider trying topical finasteride for less systemic impact, while others report mixed results and side effects.

The conversation discusses increasing the dose of oral minoxidil from 2.5mg to 5mg for better hair density, with concerns about potential side effects like heart rate changes and fluid retention. Users suggest consulting a doctor, considering individual tolerance, and exploring other treatments like dutasteride.

PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.